Maturity-Onset Diabetes of the Young Due to HNF1B Mutations
Activity Length: 16 minutes
Test Time: 4 minutes
After this activity, participants will be able to:
- Recall the pivotal role of hepatocyte nuclear factor 1β (HNF1B) in the pathogenesis of MODY, encompassing its impact on beta-cell function, glucose metabolism, and overall regulation of diabetes;
- Characterize the specific clinical presentation and features associated with MODY caused by HNF1B genetic variants, including both typical and atypical manifestations, such as renal abnormalities and extra-pancreatic involvement;
- Discuss the optimal management strategies, including lifestyle interventions, pharmacotherapy options, and the role of genetic counseling, for individuals with MODY due to HNF1B variants;
- Evaluate the long-term prognosis, potential complications, and appropriate monitoring considerations specific to this particular subtype of MODY.
Commercial Support: This CME-certified activity has not requested or received any support or funding from commercial interests. This includes but is not limited to, pharmaceutical companies and medical device manufacturers.
UNIVERSITY OF CHICAGO FACULTY
Maria V. Salguero Bermonth, MD
Clinical Pharmacology Fellow
HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum https://pubmed.ncbi.nlm.nih.gov/25536396/
Expanded Clinical Spectrum in Hepatocyte Nuclear Factor 1B-Maturity-Onset Diabetes of the Young https://academic.oup.com/jcem/article/94/7/2658/2597537
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Siri Atma Greeley, MD, PhD
Peggy Hasenauer, MS, RN
Lisa Letourneau-Freiberg, MPH, RD, LDN
Rochelle Naylor, MD
Maria Salguero Bermonth, MD, MSc
Louis Philipson, MD, PhD has received research funding from Novo Nordisk, Dompe, and Protect Bio and has served on the advisory board of Nevro.
The Center for Continuing Medical Education staff have no relevant financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 0.25 contact hours.
Other Healthcare Professional Credit